334 related articles for article (PubMed ID: 33637566)
21. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
[TBL] [Abstract][Full Text] [Related]
22. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
24. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
25. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Beltran H; Oromendia C; Danila DC; Montgomery B; Hoimes C; Szmulewitz RZ; Vaishampayan U; Armstrong AJ; Stein M; Pinski J; Mosquera JM; Sailer V; Bareja R; Romanel A; Gumpeni N; Sboner A; Dardenne E; Puca L; Prandi D; Rubin MA; Scher HI; Rickman DS; Demichelis F; Nanus DM; Ballman KV; Tagawa ST
Clin Cancer Res; 2019 Jan; 25(1):43-51. PubMed ID: 30232224
[TBL] [Abstract][Full Text] [Related]
26. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract][Full Text] [Related]
27. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
28. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract][Full Text] [Related]
29. A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma.
Wu C; Zhang HF; Gupta N; Alshareef A; Wang Q; Huang YH; Lewis JT; Douglas DN; Kneteman NM; Lai R
J Hematol Oncol; 2016 Nov; 9(1):120. PubMed ID: 27821172
[TBL] [Abstract][Full Text] [Related]
30. Role and targeting of anaplastic lymphoma kinase in cancer.
Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
[TBL] [Abstract][Full Text] [Related]
31. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
[TBL] [Abstract][Full Text] [Related]
32. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
33. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract][Full Text] [Related]
34. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
35. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
[TBL] [Abstract][Full Text] [Related]
36. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract][Full Text] [Related]
37. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
[TBL] [Abstract][Full Text] [Related]
38. Capsaicin suppressed activity of prostate cancer stem cells by inhibition of Wnt/β-catenin pathway.
Zhu M; Yu X; Zheng Z; Huang J; Yang X; Shi H
Phytother Res; 2020 Apr; 34(4):817-824. PubMed ID: 31782192
[TBL] [Abstract][Full Text] [Related]
39. ALK positively regulates MYCN activity through repression of HBP1 expression.
Claeys S; Denecker G; Durinck K; Decaesteker B; Mus LM; Loontiens S; Vanhauwaert S; Althoff K; Wigerup C; Bexell D; Dolman E; Henrich KO; Wehrmann L; Westerhout EM; Demoulin JB; Kumps C; Van Maerken T; Laureys G; Van Neste C; De Wilde B; De Wever O; Westermann F; Versteeg R; Molenaar JJ; Påhlman S; Schulte JH; De Preter K; Speleman F
Oncogene; 2019 Apr; 38(15):2690-2705. PubMed ID: 30538293
[TBL] [Abstract][Full Text] [Related]
40. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
